Linda Lindström

Linda Lindström

Principal Researcher | Docent
Telephone: +46852488117
Visiting address: BioClinicum Akademiska Stråket 1, 17164 SOLNA
Postal address: K7 Onkologi-Patologi, K7 Forskning Lindström, 171 77 Stockholm

About me

  • Associate Professor (Docent) and Group Leader
    I am Associate Professor in Cancer Epidemiology and Group Leader at the
    Department of Oncology and Pathology. In my group we do breast cancer
    research with a translational mindset. Breast cancer is the most common
    female cancer and one of the main causes of death in women. It is a
    heterogeneous disease both in the sense of primary tumor metastatic capacity
    and time to metastatic spread of disease.
    We have a specific interest in understanding the reasons behind early and
    late risk of fatal disease as is seen in patients with breast cancer. Our
    goal is to improve the prediction of patients’ risk which would allow for
    aggressive life-threatening cancers to be treated aggressively to prevent
    fatal disease, whereas sparing patients with less aggressive disease
    unnecessary treatment. My analytical background together with my research
    experience shows my strong interest in cancer and breast cancer from an
    interdisciplinary perspective.
    * 2022-2028: Cancerfonden Senior Investigator Award.
    * 2020-2021: Senior researcher position awarded by the KI Board of
    * 2015-2019: Assistant Professor position awarded by the KI Board of
    * 2015-2019: Starting grant by Vetenskapsrådet* *(Swedish Research
    * 2015-2019: Young Investigator award by FORTE.
    * 2012-2015: Postdoctoral Research position by Vetenskapsrådet.
    * 1997-2001: MSc in Molecular Biotechnology (Civilingenjör), Uppsala
    * 2004-2008: PhD in Cancer Epidemiology, MEB, KI.
    * 2008-2012: Postdoc at Onk-Pat, KI.
    * 2012-2014: Postdoc at Carol Franc Buck Breast Care Center, UCSF, USA.


  • *My main research questions:*
    * What influences the time to distant metastatic breast cancer disease and
    time of treatment benefit?
    * How does intratumor heterogeneity and tumor microenvironment impact
    patient survival?
    * Which factors are important to better understand the long-term risk to die
    from breast cancer?
    * Why do young women have a worse survival? How does the risk and benefit
    from treatment differ in premenopausal vs postmenopausal women?
    * Which benign breast diseases increase the risk for a future breast cancer
    diagnosis? Age differences?


All other publications


  • Principal Researcher, Department of Oncology-Pathology, Karolinska Institutet, 2022-

Degrees and Education

  • Docent, Karolinska Institutet, 2018
  • Degree Of Doctor Of Philosophy, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2008

News from KI

Events from KI